Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04632992 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
NCT04632992 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 252 participants.
The verdict
NCT04632992, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
Study Summary
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers. Patients will be enrolled based on local testing performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory. The multi-arm structure of the MyTACTIC study allows patients with solid tumors to be treated with a drug or drug regimen tailored to their biomarker identified at screening.
Interventions
- DRUG Atezolizumab
- DRUG Ipatasertib
- DRUG Inavolisib
- DRUG Alectinib
- DRUG Entrectinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04632992
The ClinicalTrials.gov registry entry for NCT04632992 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Atezolizumab is the first listed.
NCT04632992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04632992 about?
NCT04632992 is a clinical study titled "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response". This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific ...
What is the current status of trial NCT04632992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2021-01-13. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT04632992?
The interventions under investigation include: Atezolizumab (DRUG), Ipatasertib (DRUG), Inavolisib (DRUG), Alectinib (DRUG), Entrectinib (DRUG).
Who is sponsoring clinical trial NCT04632992?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.